PANCREATIC CANCER UK

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +25.2%

  £205,077 → £256,744

• Cash

  -2.2%

  £11,187,061 → £10,937,538

• Net assets

  -17.1%

  £6,343,648 → £5,256,372

• Employees

  +10.3%

  97 → 107

• Wages

  +21.3%

  £4,277,041 → £5,188,142

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

HaysMac LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Preparation of accounts is on a going concern basis. The trustees consider there are no material uncertainties about the Charity's ability to continue as a going concern. The review of our financial position, reserves levels and future plans gives Trustees confidence the charity remains a going concern for the foreseeable future.”

Group structure

1. PANCREATIC CANCER UK · parent
   1. Pancreatic Cancer UK Trading Limited 100% · UK · commercial activities, namely sales, promotions, mail order and licensing.

Significant events

• “2024/25 was a momentous year for Pancreatic Cancer UK. We're at a turning point - closer than ever to achieving real change for people who face pancreatic cancer.”
• “Introducing new research grant rounds to becoming the TCS London Marathon Charity of the Year, 2024/25 was such an exciting year.”
• “Our new Family History Checker, which lets people assess their risk of inheriting pancreatic cancer and take action, has already been accessed over 66,000 times, and that more than 3,000 people have self-referred for possible ongoing monitoring.”
• “We also deepened our investment in the future, committing £2.6 million to pioneering and world-class research and scientific collaborations, and investing £1.3 million in research support.”
• “We invested £2.4 million in our campaigning, policy and health improvement work. During the year we shifted up a gear to ensure that everyone with pancreatic cancer receives the high-quality care they deserve.”
• “Together, we generated a record-breaking - £13.7 million. An increase of 9% from last year despite today's challenging fundraising environment.”
• “Our community's hard work in securing our coveted status as TCS London Marathon Charity of the Year 2025 exemplifies this phenomenal collective effort and impact.”
• “In April 2024, we were thrilled to be announced as the official charity for the 2025 TCS London Marathon. It was an unprecedented opportunity to make pancreatic cancer headline news.”
• “Our powerful Shoes of Hope installation featuring 797 pairs of trainers representing the number of people lost to pancreatic cancer every month, generated wall-to-wall-media coverage.”
• “Alongside generating much-needed awareness of the cause, we've raised over £2.8 million from the partnership which will help us to fund a game-changing early detection test.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.